Fresenius Kabi (www.fresenius-kabi.com/us), an operating company of Fresenius, specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition worldwide. The company’s products and services are used for the therapy and care of patients with critical and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn and Facebook.
Fresenius Kabi and ASPEN Launch Lipid Injectable Emulsion Best Practice Video Series
January 22, 2018
SILVER SPRING, Md., January 22, 2018 - The American Society for Parenteral and Enteral Nutrition (ASPEN) and Fresenius Kabi announced today a new educational video series highlighting best practices for dosing, preparing and administering intravenous lipid emulsions (ILE). Designed for clinicians who provide nutrition support, the series address a knowledge gap between best practice recommendations and current practices in parenteral nutrition (PN). The results of a lipid survey conducted by ASPEN and published last year in the Journal of Parenteral and Enteral Nutrition1 identified this gap.
ILEs are an integral component of PN, a life-saving option for patients who can’t eat, digest or absorb enough nutrients to maintain good health.
“Lipids provide energy and essential fatty acids, and ASPEN’s survey results demonstrate a need for a better understanding of ILE provision in current practice,” said Seema Kumbhat, M.D., senior vice president and regional medical director at Fresenius Kabi in North America. “This video series is designed to educate healthcare providers on ILE best practices, such that optimal nutrition can be delivered to patients who need it.”
ASPEN’s four-part series of 15-minute videos cover:
- Rationale for ILE provision
- Dosing and administration practices
- ILE use in critically ill and non-critically ill patients
- Repackaging ILE in pediatric PN
Details and access to the videos are available on ASPEN’s website: www.nutritioncare.org/ilevideoseries.
“By sharing best practices, our hope is that these videos educate participants, help support decision-making and reduce variations in practice,” said Peggi Guenter, Ph.D, R.N., FAAN, FASPEN, senior director of clinical practice, quality and advocacy, ASPEN. “We are grateful to Fresenius Kabi for making this series possible. It provides essential background for clinicians and will help them to provide safer patient care.”
About Fresenius Kabi
The American Society for Parenteral and Enteral Nutrition (ASPEN) is dedicated to improving patient care by advancing the science and practice of nutrition support therapy and metabolism. Founded in 1976, ASPEN is an interdisciplinary organization whose members are involved in the provision of clinical nutrition therapies, including parenteral and enteral nutrition. With more than 6,500 members from around the world, ASPEN is a community of dietitians, nurses, nurse practitioners, pharmacists, physicians, scientists, students and other health professionals from every facet of nutrition support clinical practice, research and education. For more information about ASPEN, please visit www.nutritioncare.org.
Reference
1Christensen ML, Ayers PA, Boullata JI, et al. Lipid Injectable Emulsion Survey with Gap Analysis. Nutr Clin Pract 2017; Oct;32(5):694-702
Media Contacts:
Stephanie Lee
media@nutritioncare.org
301.920-9124
Matt Kuhn
Fresenius Kabi
matt.kuhn@fresenius-kabi.com
847.550.5751